Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2006
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi) technology. The company has not yet received regulatory approval for any products and has not generated revenue from product sales. Operations are funded primarily through equity offerings, strategic alliances (Novartis, Merck, Biogen Idec), and government contracts.
Key Financial Metrics
| Financial Metric (in thousands) | Three Months Ended Sep 30, 2006 |
Nine Months Ended Sep 30, 2006 |
Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Net Revenues | $8,211 | $19,949 | $4,164 |
| Net Loss | $(7,400) | $(26,170) | $(28,423) |
| Net Loss Per Share (Basic & Diluted) | $(0.23) | $(0.83) | $(1.37) |
| Research & Development Expenses | $12,833 | $37,455 | $22,557 |
| General & Administrative Expenses | $3,982 | $12,004 | $10,162 |
| Cash and Cash Equivalents (End of Period) | $35,516 | $35,516 | $7,178 |
| Marketable Securities (End of Period) | $84,758 | $84,758 | $N/A |
| Total Debt (Notes Payable) | $9,483 | $9,483 | $N/A |
| Accumulated Deficit | $(132,089) | $(132,089) | $(105,919) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased significantly to $19.9 million for the nine months ended September 30, 2006, compared to $4.2 million in the prior year period. This was driven primarily by collaboration revenues from Novartis ($17.2 million) and the Novartis Pandemic Flu Alliance ($2.9 million).
- Expense Increases: Research and development (R&D) expenses rose 66% year-over-year to $37.5 million, primarily due to clinical trial and manufacturing costs for the RSV program and increased license fees. General and administrative (G&A) expenses increased 18% to $12.0 million, largely due to the adoption of SFAS 123R (stock-based compensation) and facility expansion.
- Liquidity Improvement: Cash and cash equivalents increased from $15.8 million at year-end 2005 to $35.5 million at September 30, 2006. Total liquid assets (cash + marketable securities) reached $120.3 million, bolstered by a $62.2 million follow-on public offering in January 2006.
- Net Loss Reduction: Despite higher operating expenses, the net loss for the nine months ended September 30, 2006, decreased to $26.2 million from $28.4 million in the prior year, aided by higher interest income ($4.4 million vs. $0.8 million) due to increased cash balances.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur significant additional losses over the next several years as R&D activities expand. The company believes existing resources and expected collaboration revenues will fund operations beyond the end of 2007.
- Clinical Progress: Phase I trials for ALN-RSV01 (RSV treatment) were completed in May 2006 with positive safety results. A Phase I study with an inhaled formulation began in October 2006, with a Phase II trial planned for the first half of 2007. The timeline for the influenza program (ALN-FLU01) has shifted to 2007 for IND filing.
- New Agreements:
- Biogen Idec: Entered a collaboration in September 2006 for PML treatment, receiving a $5.0 million upfront payment.
- Ebola Contract: Awarded a contract by the NIAID for up to $23 million over four years to develop an anti-viral therapeutic against hemorrhagic fever viruses, including Ebola.
- Risks:
- Technology Risk: RNAi is an unproven technology; no RNAi therapeutics have received regulatory approval.
- Capital Needs: The company requires substantial additional funds for clinical trials and may need to raise capital through equity or debt, potentially causing dilution.
- Collaboration Dependence: A significant portion of revenue and funding relies on strategic alliances (Novartis, Merck). Termination or failure of these collaborations would materially harm the business.
- Regulatory Uncertainty: The FDA has not established definitive policies for RNAi drugs, creating uncertainty in the approval process.
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of revenue streams, as the majority of 2006 revenue ($17.2 million) is derived from the Novartis collaboration.
- Cash Burn Rate: Monitor the net cash used in operating activities ($20.0 million for the nine months) against the current cash balance to assess runway without further financing.
- Stock-Based Compensation: Note the impact of SFAS 123R adoption, which added $4.5 million to expenses for the nine months ended September 30, 2006.
- Debt Obligations: Review the terms of the $9.5 million outstanding debt (Oxford Finance and Lighthouse Capital), including interest rates (approx. 9.25% - 10.41%) and repayment schedules.
- Intellectual Property: Assess the status of patent litigation and oppositions, particularly regarding the Kreutzer-Limmer patent in Europe, which is critical to the company's technology platform.